BAO PHAM: Open Payments
NPI 1417098500 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,187 in 57 payments from 18 companies in 2025. Trend: 2023 $1,145 · 2024 $1,551 · 2025 $1,187
Food & beverage: $1,187
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $184 |
| Novo Nordisk Inc | 8 | $154 |
| AstraZeneca Pharmaceuticals LP | 4 | $137 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $125 |
| Amgen Inc. | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Lilly USA, LLC | 3 | $60 |
| Dexcom, Inc. | 2 | $60 |
| Exact Sciences Corporation | 3 | $54 |
| Gilead Sciences, Inc. | 2 | $53 |
Products named: Kerendia, TRELEGY ELLIPTA, Ozempic, BREZTRI, GVOKE HYPOPEN, MOUNJARO, Dexcom G6 Transmitter, OTEZLA.
Industry payments across TX — which companies pay providers there.
